[go: up one dir, main page]

IN2014MU00303A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00303A
IN2014MU00303A IN303MU2014A IN2014MU00303A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A IN 303MU2014 A IN303MU2014 A IN 303MU2014A IN 2014MU00303 A IN2014MU00303 A IN 2014MU00303A
Authority
IN
India
Prior art keywords
pharmaceutical composition
relates
abiraterone
abstract
preparing
Prior art date
Application number
Inventor
Geena Malhotra
Preeti Raut
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to IN303MU2014 priority Critical patent/IN2014MU00303A/en
Priority to PCT/GB2015/050175 priority patent/WO2015114314A1/en
Publication of IN2014MU00303A publication Critical patent/IN2014MU00303A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Abstract The present invention relates to relates to a pharmaceutical composition comprising abiraterone and one or more pharmaceutically acceptable excipients, to a process for preparing such pharmaceutical composition and to the use of the said pharmaceutical composition for the treatment of prostate cancer.
IN303MU2014 2014-01-28 2015-01-27 IN2014MU00303A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN303MU2014 IN2014MU00303A (en) 2014-01-28 2015-01-27
PCT/GB2015/050175 WO2015114314A1 (en) 2014-01-28 2015-01-27 Pharmaceutical composition comprising abiraterone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN303MU2014 IN2014MU00303A (en) 2014-01-28 2015-01-27

Publications (1)

Publication Number Publication Date
IN2014MU00303A true IN2014MU00303A (en) 2015-09-11

Family

ID=52462940

Family Applications (1)

Application Number Title Priority Date Filing Date
IN303MU2014 IN2014MU00303A (en) 2014-01-28 2015-01-27

Country Status (2)

Country Link
IN (1) IN2014MU00303A (en)
WO (1) WO2015114314A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824908A1 (en) 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
US20190209469A1 (en) * 2016-08-20 2019-07-11 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CA3098208A1 (en) 2018-04-26 2019-10-31 Synthon B.V. Tablet compositions comprising abiraterone acetate
CA3124439A1 (en) * 2018-12-20 2020-06-25 Pharmaceutical Oriented Services Ltd Dosage form containing abiraterone acetate
US12403149B2 (en) 2019-07-15 2025-09-02 Shilpa Medicare Limited Dispersible tablets of abiraterone acetate
MX2022004808A (en) * 2019-10-22 2022-06-08 Arvinas Operations Inc Methods of treating prostate cancer.
CN113384532B (en) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 CYP17 inhibitor solid dispersion and preparation method thereof
CN115996918A (en) 2020-05-09 2023-04-21 阿尔维纳斯运营股份有限公司 Process for the manufacture of bifunctional compounds, ultrapure forms of bifunctional compounds, and dosage forms comprising said bifunctional compounds
EP3944860A1 (en) * 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
CN115475172B (en) * 2021-06-15 2023-12-01 北京泰德制药股份有限公司 A pharmaceutical composition containing abiraterone or its pharmaceutically acceptable salt
WO2025122895A1 (en) 2023-12-08 2025-06-12 Arvinas Operations, Inc. Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3578A (en) * 2010-10-01 2016-02-08 Cipla Ltd Pharmaceutical composition comprising deferasirox
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
KR20160023641A (en) * 2013-03-15 2016-03-03 아이슈티카 인코포레이티드 Abiraterone acetate formulation

Also Published As

Publication number Publication date
WO2015114314A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
IN2014MU00303A (en)
MX2023010042A (en) Modulatory polynucleotides.
HUE054316T2 (en) Pharmaceutical composition for cancer treatment
TW201613901A (en) New compounds
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
GB2541571A (en) Pharmaceutical compositions
NZ725480A (en) Anti-ptk7 antibody-drug conjugates
HUE055433T2 (en) Combined preparations for the treatment of cancer
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
PH12016501841A1 (en) Immunosuppressant formulation
PH12017500239A1 (en) Abiraterone acetate formulation and methods of use
MX2017002489A (en) Human therapeutic agents.
WO2015123449A3 (en) Compositions and methods of using microrna inhibitors
MX2018003563A (en) New compounds.
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
PH12017500602A1 (en) Methods for treating ocular conditions
IL266486A (en) Pharmaceutical compositions and methods for the treatment of cancer
MX382092B (en) Heterocyclic compounds for the treatment of disease
MX2020000135A (en) New quinolinone compounds.
IL275525A (en) Pharmaceutical composition for the treatment of cancer
HK1254231A1 (en) Mito-honokiol compounds and methods of synthesis and use thereof
IN2014MU00495A (en)
GB201719584D0 (en) Pharmaceutical compositions for the treatment of cancer
PT3580211T (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer